Below are the most recent publications written about "Vaccines, Combined" by people in Profiles.
-
To A, Wong TAS, Ball AH, Lieberman MM, Yalley-Ogunro J, Cabus M, Nezami S, Paz F, Elyard HA, Borisevich V, Agans KN, Deer DJ, Woolsey C, Cross RW, Geisbert TW, Donini O, Lehrer AT. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection. Vaccine. 2024 Jan 25; 42(3):598-607.
-
Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, B?cker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, McQuarrie LJ, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial. J Infect Dis. 2023 12 20; 228(12):1662-1666.
-
Branche AR, Rouphael NG, Losada C, Baden LR, Anderson EJ, Luetkemeyer AF, Diemert DJ, Winokur PL, Presti RM, Kottkamp AC, Falsey AR, Frey SE, Rupp R, B?cker M, Novak RM, Walter EB, Jackson LA, Little SJ, Immergluck LC, Mahgoub SM, Whitaker JA, Babu TM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
-
Wightman P, McCue K, Sabo S, Annorbah R, Jim?nez D, Pilling V, Butler M, Celaya MF, Rumann S. Community health worker intervention improves early childhood vaccination rates: results from a propensity-score matching evaluation. BMC Public Health. 2022 10 04; 22(1):1854.
-
Campuzano A, Zhang H, Ostroff GR, Dos Santos Dias L, W?thrich M, Klein BS, Yu JJ, Lara HH, Lopez-Ribot JL, Hung CY. CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine against Coccidioides posadasii Infection. J Immunol. 2020 06 15; 204(12):3296-3306.
-
Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine. 2011 May 12; 29(21):3802-10.
-
Nyamathi A, Sinha K, Greengold B, Cohen A, Marfisee M. Predictors of HAV/HBV vaccination completion among methadone maintenance clients. Res Nurs Health. 2010 Apr; 33(2):120-32.
-
Nyamathi A, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, Leake B, Tyler D, Gelberg L. Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults. Nurs Res. 2009 Jan-Feb; 58(1):13-22.
-
Igietseme JU, Eko FO, He Q, Black CM. Combination vaccines: design strategies and future trends. Expert Rev Vaccines. 2006 Dec; 5(6):739-45.
-
Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol. 2007 Feb; 49(1):46-55.